| NEUROCRINE-BIOSCIENCES-INC |
NEUROCRINE-BIOSCIENCES-INC |
92%
|
the Company granted Neurocrine an exclusive worldwide license to a discovery research program targeting ATXN2, or the Neurocrine License Agreement |
| SHIONOGI |
SHIONOGI |
92%
|
the Company granted Shionogi an exclusive, worldwide, sublicensable license to research, develop, manufacture and commercialize MZE001 and certain other small molecule compounds modulating glycogen s… |
| TRACE-NEUROSCIENCE-INC |
TRACE-NEUROSCIENCE-INC |
92%
|
the Company granted an exclusive worldwide license to a discovery research program targeting UNC13A for the treatment of amyotrophic lateral sclerosis, or the Trace License Agreement |
| NBIX |
Neurocrine Biosciences, Inc. |
85%
|
. Potential sales milestones and royalties on net product sales will be recognized in the same period that the underlying net product sales occur as they were determined to relate to the license. The… |
| NBIX |
Neurocrine Biosciences, Inc. |
85%
|
Reciprocal relationship from NBIX graph: Reciprocal relationship from MAZE graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from MAZE graph: . Potential sales milestones and ro… |
| DYN |
Dyne Therapeutics, Inc. |
72%
|
Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number… |
| HTGC |
Hercules Capital, Inc. |
72%
|
ment of our Maze Compass platform, or our Compass platform, planned preclinical studies, IND filings and clinical trials for future therapeutic candidates. We will also incur substantial additional e… |
| HTGC |
Hercules Capital, Inc. |
72%
|
Reciprocal relationship from HTGC graph: Reciprocal relationship from MAZE graph: ment of our Maze Compass platform, or our Compass platform, planned preclinical studies, IND filings and clinical tri… |
| SGIOF |
Shionogi & Co., Ltd. |
72%
|
ecognized over a weighted average period of 1.67 years. 8. License agreements Trace License Agreement In March 2024, the Company entered into an exclusive license agreement with Trace Neuroscience, I… |
| SGIOF |
Shionogi & Co., Ltd. |
72%
|
Reciprocal relationship from SGIOF graph: Reciprocal relationship from MAZE graph: Reciprocal relationship from SGIOF graph: Reciprocal relationship from MAZE graph: Reciprocal relationship from SGIO… |
| SNYNF |
Sanofi |
72%
|
cal trials for our lead programs may not be predictive of the results of outcomes in subsequent clinical trials. Later-stage clinical trials could differ in significant ways from early-stage clinical… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from MAZE graph: cal trials for our lead programs may not be predictive of the results of outcomes in subsequent clinical trials. Lat… |
| ALLOY-THERAPEUTICS-INC |
ALLOY-THERAPEUTICS-INC |
62%
|
cal trials for our lead programs may not be predictive of the results of outcomes in subsequent clinical trials. Later-stage clinical trials could differ in significant ways from early-stage clinical… |
| BROADWING-BIO-LLC |
BROADWING-BIO-LLC |
62%
|
cal trials for our lead programs may not be predictive of the results of outcomes in subsequent clinical trials. Later-stage clinical trials could differ in significant ways from early-stage clinical… |
| CO-LTD |
CO-LTD |
62%
|
ecognized over a weighted average period of 1.67 years. 8. License agreements Trace License Agreement In March 2024, the Company entered into an exclusive license agreement with Trace Neuroscience, I… |
| COMPANY-LTD |
COMPANY-LTD |
62%
|
Item 1 of this Annual Report on Form 10-K for additional details. In September 2025, we announced positive clinical results from our Phase 1 healthy volunteer study of MZE782. We plan to initiate two… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
pplication include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In … |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
pplication include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In … |
